Literature DB >> 9684195

Phenytoin hypersensitivity syndrome with positive patch test. A possible cross-reactivity with amitriptyline.

P A Galindo Bonilla1, G Romero Aguilera, F Feo Brito, E Gómez Torrijos, R García Rodríguez, P Cortina de la Calle, C Encinas Barrios.   

Abstract

A 34-year-old woman, after 2 weeks of treatment with phenytoin and amitriptyline, developed fever and cutaneous lesions consisting of a generalized maculopapular rash and eosinophilia. Her biochemical data showed abnormal liver functions with increased levels of SGOT, SGPT, LDH, gamma-glutamyl transpeptidase and alkaline phosphatase. The skin biopsy pattern was compatible with phenytoin drug eruption of the erythemamultiforme-like type (lymphocytic exocytosis, isolated dyskeratotic cells, vacuolation of basal cells and incontinence of pigment). The patch tests were positive with phenytoin (patch test biopsy showed a typical eczematous pattern). The patch test with amitriptyline was negative. An oral challenge with amitriptyline showed an erythematous maculopapular rash. The challenge with phenytoin was not carried out because the previously abnormal liver function tests contraindicated the challenge. Although there are a few cases reported, the patch tests could be useful for diagnosing phenytoin allergy. Cross-reactivity between phenytoin and amitriptyline is possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684195

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  2 in total

1.  [DRESS syndrome after carbamazepine].

Authors:  G Wurpts; H Ott; A Schlüter; M Häusler
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

Review 2.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.